This HTML5 document contains 66 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00686/identifier/pubchem-compound/
n19http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n5http://linked.opendata.cz/resource/drugbank/company/
n16http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00686/identifier/pubchem-substance/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00686/identifier/drugbank/
n17http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n12http://linked.opendata.cz/resource/drugbank/patent/
n7http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n13http://linked.opendata.cz/resource/drugbank/drug/DB00686/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n22http://www.rxlist.com/cgi/generic2/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n20http://linked.opendata.cz/resource/drugbank/drug/DB00686/identifier/pharmgkb/
n18http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00686
rdf:type
n3:Drug
n3:description
A sulfated pentosyl polysaccharide with heparin-like properties. [PubChem]
n3:dosage
n16:271B451F-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
4.8 hours
n3:indication
For the relief of bladder pain or discomfort associated with interstitial cystitis.
n3:manufacturer
n5:271B451D-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00686 n17:DB00686
dcterms:title
Pentosan Polysulfate
adms:identifier
n11:DB00686 n13:34595 n14:37720 n15:46509187 n20:PA164774806
n3:mechanismOfAction
Pentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.
n3:packager
n5:271B451B-363D-11E5-9242-09173F13E4C5 n5:271B451C-363D-11E5-9242-09173F13E4C5 n5:271B4519-363D-11E5-9242-09173F13E4C5 n5:271B451A-363D-11E5-9242-09173F13E4C5 n5:271B4517-363D-11E5-9242-09173F13E4C5 n5:271B4518-363D-11E5-9242-09173F13E4C5 n5:271B4515-363D-11E5-9242-09173F13E4C5 n5:271B4516-363D-11E5-9242-09173F13E4C5
n3:patent
n12:5180715
n3:synonym
Pentosane polysulfate Pentosano polisulfato Pentosani polysulfas Pentosanpolysulfat Pentosan sulfuric polyester
n18:hasAHFSCode
n19:92-00-00
n3:foodInteraction
Take on an empty stomach, 1 hour before or 2 hours after meals.
n3:salt
n3:synthesisReference
Pandurang Balwant Deshpande, Parvenkumar Luthra, Anand Kumar Pandey, Dinesh Jayntibhai Paghdar, Phani,Sharma,Gowthamaiah Vemavarapu Govardhana, "PROCESS FOR THE PREPARATION OF PENTOSAN POLYSULFATE OR SALTS THEREOF." U.S. Patent US20100105889, issued April 29, 2010.
foaf:page
n22:pento.htm
n3:IUPAC-Name
n4:271B4524-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B452A-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B4529-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B4526-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B4527-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B4528-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B4522-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B4523-363D-11E5-9242-09173F13E4C5 n4:271B453A-363D-11E5-9242-09173F13E4C5 n4:271B4520-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B4521-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B4530-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B4531-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B452B-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B452C-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B452E-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B452D-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B452F-363D-11E5-9242-09173F13E4C5
n3:absorption
Slow
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
37300-21-3
n3:containedIn
n8:271B451E-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B4536-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B4538-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B4539-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B4535-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B4534-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B4537-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B4525-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B4532-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B4533-363D-11E5-9242-09173F13E4C5